全文获取类型
收费全文 | 100679篇 |
免费 | 6139篇 |
国内免费 | 437篇 |
专业分类
耳鼻咽喉 | 1113篇 |
儿科学 | 2518篇 |
妇产科学 | 1784篇 |
基础医学 | 12482篇 |
口腔科学 | 1755篇 |
临床医学 | 10661篇 |
内科学 | 20254篇 |
皮肤病学 | 1339篇 |
神经病学 | 10082篇 |
特种医学 | 3900篇 |
外国民族医学 | 3篇 |
外科学 | 16344篇 |
综合类 | 1083篇 |
一般理论 | 131篇 |
预防医学 | 8234篇 |
眼科学 | 2080篇 |
药学 | 6488篇 |
中国医学 | 105篇 |
肿瘤学 | 6899篇 |
出版年
2023年 | 564篇 |
2022年 | 935篇 |
2021年 | 2096篇 |
2020年 | 1327篇 |
2019年 | 2101篇 |
2018年 | 2551篇 |
2017年 | 1826篇 |
2016年 | 1988篇 |
2015年 | 2275篇 |
2014年 | 3444篇 |
2013年 | 4730篇 |
2012年 | 7564篇 |
2011年 | 7975篇 |
2010年 | 4587篇 |
2009年 | 4133篇 |
2008年 | 7125篇 |
2007年 | 7452篇 |
2006年 | 7180篇 |
2005年 | 6897篇 |
2004年 | 6719篇 |
2003年 | 6051篇 |
2002年 | 5708篇 |
2001年 | 839篇 |
2000年 | 558篇 |
1999年 | 891篇 |
1998年 | 1219篇 |
1997年 | 926篇 |
1996年 | 748篇 |
1995年 | 682篇 |
1994年 | 589篇 |
1993年 | 578篇 |
1992年 | 441篇 |
1991年 | 399篇 |
1990年 | 322篇 |
1989年 | 292篇 |
1988年 | 277篇 |
1987年 | 277篇 |
1986年 | 241篇 |
1985年 | 279篇 |
1984年 | 307篇 |
1983年 | 254篇 |
1982年 | 333篇 |
1981年 | 281篇 |
1980年 | 221篇 |
1979年 | 93篇 |
1978年 | 128篇 |
1977年 | 108篇 |
1976年 | 78篇 |
1975年 | 66篇 |
1973年 | 69篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Mark J. Niciu David A. Luckenbaugh Dawn F. Ionescu Erica M. Richards Jennifer L. Vande Voort Elizabeth D. Ballard Nancy E. Brutsche Maura L. Furey Carlos A. Zarate Jr 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2015,18(1)
Background:
A single subanesthetic infusion of the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has rapid and potent antidepressant properties in treatment-resistant major depressive disorder (TRD). As a family history of an alcohol use disorder is a positive predictor of ketamine’s antidepressant response and the strength of the association increases over time, we hypothesized that depressed subjects with a family history of an alcohol use disorder would have greater antidepressant durability and that riluzole would augment and/or extend ketamine’s antidepressant efficacy.Methods:
Fifty-two TRD subjects received an open-label infusion of ketamine (0.5mg/kg over 40 minutes), and, four to six hours post-infusion, were randomized to either flexible-dose (100–200mg/day) riluzole or placebo in the following proportions: Family History Positive (FHP) riluzole (n = 10), FHP placebo (n = 9), Family History Negative (FHN) riluzole (n = 16), and FHN placebo (n = 17).Results:
FHP subjects randomized to placebo had a greater antidepressant response than FHN subjects; however, contrary to our initial hypothesis, there was no significant difference in antidepressant efficacy with riluzole. Although potentially underpowered, there was no difference in overall time-to-relapse based on randomization status (riluzole responders: n = 15, placebo responders: n = 17). Yet, time-to-relapse was longer in FHP placebo responders (n = 8) compared to FHN placebo responders (n = 9) with, again, no significant difference in time-to-relapse in FHP riluzole responders (n = 6) compared to FHN riluzole responders (n = 9).Conclusions:
Ketamine’s extended antidepressant durability in FHP TRD should be considered in the design and analysis of ketamine depression trials. 相似文献992.
993.
Jeffrey J. Talbot Dominador Calamba Melody Pai Mark Ma Theingi M. Thway 《The AAPS journal》2015,17(6):1446-1454
Decisions about efficacy and safety of therapeutic proteins (TP) designed to target soluble ligands are made in part by their ex vivo quantification. Ligand binding assays (LBAs) are critical tools in measuring serum TP levels in pharmacokinetic, toxicokinetic, and pharmacodynamic studies. This study evaluated the impact of reagent antibody affinities, assay incubation times, and analytical platform on free or total TP quantitation. An ELISA-based LBA that measures monoclonal anti-sclerostin antibody (TPx) was used as the model system. To determine whether the method measures free or total TPx, the effects of Kon, Koff, and KD were determined. An 8:1 molar ratio of sclerostin (Scl) to TPx compared to a 1:1 molar ratio produced by rabbit polyclonal antibodies to TPx was required to achieve IC50, a measure of TPx interference effectiveness, making it unclear whether the ELISA truly measured free TPx. Kinetic analysis revealed that Scl had a rapid dissociation rate (Koff) from TPx and that capture and detection antibodies had significantly higher binding affinities (KD) to TPx. These kinetic limitations along with long ELISA incubation times lead to the higher molar ratios (8:1) required for achieving 50% inhibition of TPx. However, a microfluidic platform with the same reagent pairs required shorter incubations to achieve a lower Scl IC50 molar ratio (1:1). The findings from this study provide the bioanalytical community with a deeper understanding of how reagent and platform selection for LBAs can affect what a particular method measures, either free or total TP concentrations.KEY WORDS: affinity and kinetics, association and dissociation, free versus total, interference, ligand binding assay 相似文献
994.
995.
996.
Saloumeh K. Fischer Alison Joyce Mark Spengler Tong-Yuan Yang Yao Zhuang Marianne Scheel Fjording Alvydas Mikulskis 《The AAPS journal》2015,17(1):93-101
Ligand binding assays (LBAs) have been the method of choice for protein analyte measurements for more than four decades. Over the years, LBA methods have improved in sensitivity and achieved larger dynamic ranges by using alternative detection systems and new technologies. As a consequence, the landscape and application of immunoassay platforms has changed dramatically. The introduction of bead-based methods, coupled with single molecule detection standardization and the ability to amplify assay signals, has improved the sensitivity of many immunoassays, in some cases by several logs of magnitude. Three promising immunoassay platforms are described in this article: Single Molecule Counting (SMC™) from Singulex Inc, Single Molecule Arrays (Simoa™) from Quanterix Corporation, and Immuno-PCR (Imperacer®) from Chimera Biotec GmbH. These platforms have the potential to significantly improve immunoassay sensitivity and thereby address the bioanalytical needs and challenges faced during biopharmaceutical drug development.KEY WORDS: immunoassays, Immuno-PCR (Chimera Biotec GmbH), ligand binding assay (LBA), sensitivity, Single Molecule Array (Quanterix Corporation), Single Molecule Counting (Singulex Inc) 相似文献
997.
998.
999.
David A. Talan Sukhjit S. Takhar Anusha Krishnadasan William R. Mower Daniel J. Pallin Manish Garg Jon Femling Richard E. Rothman Johanna C. Moore Alan E. Jones Frank Lovecchio Jonathan Jui Mark T. Steele Amy M. Stubbs William K. Chiang Gregory J. Moran 《Annals of emergency medicine》2021,77(1):32-43
1000.